NARA Discovery
Article Details
← Back to Search Results
Journal Article

Knockdown of nicotinamide N-methyltransferase suppresses proliferation, migration, and chemoresistance of Merkel cell carcinoma cells in vitro

Valentina Pozzi; Elisa Molinelli; Roberto Campagna; Emma N. Serritelli; Monia Cecati; Edoardo De Simoni; Davide Sartini; Gaia Goteri; Nathaniel I. Martin; Matthijs J. van Haren; Eleonora Salvolini; Oriana Simonetti; Annamaria Offidani; Monica Emanuelli
Human Cell · Vol. 37, Issue 3 · pp. 729-738 · 2024

Abstract

Merkel cell carcinoma (MCC) is an aggressive skin cancer, with a propensity for early metastasis. Therefore, early diagnosis and the identification of novel targets become fundamental. The enzyme nicotinamide N -methyltransferase (NNMT) catalyzes the reaction of N -methylation of nicotinamide and other analogous compounds. Although NNMT overexpression was reported in many malignancies, the significance of its dysregulation in cancer cell phenotype was partly clarified. Several works demonstrated that NNMT promotes cancer cell proliferation, migration, and chemoresistance. In this study, we investigated the possible involvement of this enzyme in MCC. Preliminary immunohistochemical analyses were performed to evaluate NNMT expression in MCC tissue specimens. To explore the enzyme function in tumor cell metabolism, MCC cell lines have been transfected with plasmids encoding for short hairpin RNAs (shRNAs) targeting NNMT mRNA. Preliminary immunohistochemical analyses showed elevated NNMT expression in MCC tissue specimens. The effect of enzyme downregulation on cell proliferation, migration, and chemosensitivity was then evaluated through MTT, trypan blue, and wound healing assays. Data obtained clearly demonstrated that NNMT knockdown is associated with a decrease of cell proliferation, viability, and migration, as well as with enhanced sensitivity to treatment with chemotherapeutic drugs. Taken together, these results suggest that NNMT could represent an interesting MCC biomarker and a promising target for targeted anti-cancer therapy.

Bibliographic Information

JournalHuman Cell
PublisherSpringer
Publication Date2024-03-19
Publication Year2024
Volume37
Issue3
Pages729-738
Document TypeJournal Article
eISSN1749-0774
DOI10.1007/s13577-024-01047-0

Access Information

NARA Access Coverage2002-01-01~Current
Journal Homepagehttps://www.springer.com/journal/13577
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.